What is the mechanism of action of the GLP-2 analog, teduglutide, for GvHD treatment?
A four-minute talk by Robert Zeiser on how the GLP-2 analog teduglutide acts on the gut in graft-versus-host disease, based on preclinical and patient data.
With Robert Zeiser (Director of the Division of Tumor Immunology, Freiburg University Medical Center)
Key moments
Tap a moment to play the video from there.
- 0:06Introduction and GLP-2 basicsZeiser introduces himself and describes GLP-2 as a gut hormone peptide made by L-cells.
- 0:38GLP-2 drops in GvHDHe reports that gut GLP-2 levels were reduced in preclinical studies and in patients with GvHD. He says teduglutide, with its longer half-life, reduced acute and steroid-refractory GvHD.
- 1:08Paneth cells and microbiomeZeiser says GLP-2 replacement promoted regeneration of Paneth cells, which produce antimicrobial peptides and influence the microbiome.
- 1:39Intestinal stem cell regenerationHe explains that GLP-2 promoted intestinal stem cells, which he says drive regeneration of the damaged gut.
- 2:11Organoids and patient dataHe describes expanded intestinal organoids and reduced apoptosis-related gene expression. He also cites patient data linking low L-cell numbers and high serum GLP-2 to non-relapse mortality.
- 2:43L-cells as a GvHD targetZeiser summarizes that L-cells are affected in GvHD and that GLP-2 based treatment may restore gut balance through stem cells and Paneth cells.
- 3:13Graft-versus-leukemia effect preservedHe says several preclinical leukemia models showed no impact of GLP-2 on the anti-leukemic immune response.
- 3:43Outlook for clinical trialsZeiser proposes teduglutide as a regenerative approach and combination partner for immunosuppressive therapy, to be tested in future trials.
What the video says
Robert Zeiser, who introduces himself as director of the division of tumor immunology at Freiburg University Medical Center, explains how glucagon-like peptide 2 (GLP-2) relates to graft-versus-host disease (GvHD). He describes GLP-2 as a peptide made by intestinal L-cells, and says GLP-2 levels in the gut fell in preclinical studies of acute GvHD and in patients who developed the condition.
Zeiser then describes work with teduglutide, a GLP-2 analog with a longer half-life than the natural peptide. According to him, teduglutide reduced de novo acute GvHD and steroid-refractory GvHD in several preclinical models, without weakening the graft-versus-leukemia effect. He presents this as a central point of the talk.
On mechanism, Zeiser says GLP-2 supported the regeneration of Paneth cells, which make antimicrobial peptides and shape the composition of the gut microbiome. He also says it supported intestinal stem cells, which he describes as important for regeneration of the damaged intestinal tract. He adds that GLP-2 expanded intestinal organoids and lowered the expression of apoptosis-related genes in intestinal cells.
He also cites a collaboration with a colleague in Hamburg. In biopsies and serum from patients undergoing allogeneic stem cell transplantation, low L-cell numbers and high serum GLP-2 were linked to a higher rate of non-relapse mortality. Zeiser concludes that L-cells are a target of GvHD and that teduglutide could become a regenerative approach and a combination partner for immunosuppressive GvHD therapy, which he says should be tested in future clinical trials.
On each compound
GLP-20:38
Zeiser describes GLP-2 as a gut peptide from L-cells and teduglutide as a longer-lasting analog. He says teduglutide reduced acute and steroid-refractory GvHD in preclinical models without affecting the graft-versus-leukemia response, and that it supported Paneth cells and intestinal stem cells.
See how your DNA reads GLP-2What this video doesn’t settle
- The talk presents preclinical results and association data and does not report any clinical trial of teduglutide in GvHD patients.
- No doses, schedules, or numerical results are given, so the size of any effect cannot be judged from the video.
- The patient finding linking low L-cell numbers and high serum GLP-2 to non-relapse mortality is an association, and the talk does not explain why high levels would accompany worse outcomes.
Questions this video answers
How does teduglutide work in graft-versus-host disease?
According to Zeiser, teduglutide is a long-acting GLP-2 analog. He says it promotes regeneration of intestinal stem cells and Paneth cells, which make antimicrobial peptides and shape the microbiome, and it reduces expression of apoptosis-related genes in intestinal cells.
Does GLP-2 interfere with the graft-versus-leukemia effect?
Zeiser says that in the different preclinical leukemia models his group used, GLP-2 had no impact on the anti-leukemic immune response. He notes this is important whenever the immune system is modified in a host with a malignancy.
What are L-cells and why do they matter in GvHD?
Zeiser describes L-cells as the intestinal cells that produce GLP-2. He says they are a target of GvHD, and that low L-cell numbers in biopsies were linked in patients to higher non-relapse mortality.
Has teduglutide been proven in GvHD patients?
No. Zeiser says the findings point to teduglutide as a possible regenerative approach and combination partner, and that it should be tested in future clinical trials.
Video by GvHD Hub on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
